Expanded Access Protocol
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib.
Expanded Access, also known as “compassionate use,” refers to the use of an investigational therapy outside of a clinical trial. This is a U.S. Food and Drug Administration (FDA) initiative that allows patients with serious illnesses, who have exhausted all other treatment options, the opportunity to access investigational drugs that are not yet approved. For more information on the FDA Expanded Access program, please see the FDA website on Expanded Access, and/or talk to your health care provider.
At this time, Sierra Oncology does not provide access to investigational therapies, except for patients who are enrolled in a clinical trial. Sierra Oncology understands the need for Expanded Access programs and may revise this policy at any time. For information on clinical trial participation and status updates, please check www.clinicaltrials.gov. If you have additional questions, please speak with your health care provider or contact email@example.com. We anticipate acknowledging receipt of requests sent to this email within ten business days.